 Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration FDA for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied. 